Physician profile
Daniel J Hendrick
NPI 1295790707
$7,008.15
in general payments reported to CMS, 2019-2025
33 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $587 · 2021: $450 · 2022: $959 · 2023: $1,415 · 2024: $1,596 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,389.92 |
| Education | $119.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $983.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $877.72 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $739.25 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $643.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.25 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $350.43 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Ardelyx, INC. | $326.36 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Amgen INC. | $317.10 | 2019-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $266.31 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $263.89 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $262.17 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $174.27 | 2019-2023 | Ultomiris |
| Daiichi Sankyo INC. | $145.42 | 2020-2024 | Injectafer |
| Horizon Therapeutics Plc | $135.14 | 2020-2023 | Krystexxa |
| Novo Nordisk INC | $123.02 | 2024-2025 | Ozempic, Wegovy, Rivfloza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $115.68 | 2019-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $92.31 | 2019-2021 | |
| Outset Medical INC | $80.02 | 2024 | |
| Mallinckrodt Hospital Products INC. | $78.78 | 2020-2025 | Terlivaz |
| Glaxosmithkline, LLC. | $71.49 | 2021-2025 | Benlysta |
| Takeda Pharmaceuticals U.S.A., INC. | $52.37 | 2023 | Gattex |
| Ultragenyx Pharmaceutical INC. | $48.04 | 2020-2024 | Crysvita |
| Amicus Therapeutics, INC. | $47.51 | 2022 | |
| Shire North American Group INC | $43.80 | 2019 | |
| Genentech USA, INC. | $36.49 | 2019-2025 | Gazyva |
| Abiomed | $29.10 | 2025 | |
| Ani Pharmaceuticals, INC. | $29.00 | 2024 | Purified Cortrophin Gel |
| W. L. Gore & Associates, INC. | $26.75 | 2024 | Gore Acuseal Vascular Graft |
| Alnylam Pharmaceuticals INC. | $25.81 | 2021 | |
| Pharmacosmos Therapeutics INC. | $25.45 | 2024 | Monoferric |
| Akebia Therapeutics INC | $24.79 | 2020 | |
| Genzyme Corporation | $17.62 | 2019 | |
| Strongbridge US INC. | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.